Sterling Investment Management LLC Has $369,000 Holdings in Johnson & Johnson $JNJ

Sterling Investment Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 86.8% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,453 shares of the company’s stock after selling 9,516 shares during the quarter. Sterling Investment Management LLC’s holdings in Johnson & Johnson were worth $369,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. JM2 Capital Inc. raised its stake in shares of Johnson & Johnson by 2.9% in the second quarter. JM2 Capital Inc. now owns 3,827 shares of the company’s stock worth $972,000 after purchasing an additional 107 shares during the last quarter. Madson Wealth Advisors Inc lifted its holdings in shares of Johnson & Johnson by 6.7% in the second quarter. Madson Wealth Advisors Inc now owns 7,597 shares of the company’s stock valued at $1,929,000 after purchasing an additional 478 shares in the last quarter. Ifrah Financial Services Inc. boosted its position in shares of Johnson & Johnson by 40.1% during the second quarter. Ifrah Financial Services Inc. now owns 4,786 shares of the company’s stock valued at $1,216,000 after buying an additional 1,370 shares during the last quarter. River Street Advisors LLC grew its holdings in Johnson & Johnson by 1.5% during the second quarter. River Street Advisors LLC now owns 13,317 shares of the company’s stock worth $3,382,000 after buying an additional 199 shares in the last quarter. Finally, Portus Wealth Advisors LLC grew its holdings in Johnson & Johnson by 5.8% during the second quarter. Portus Wealth Advisors LLC now owns 6,055 shares of the company’s stock worth $1,538,000 after buying an additional 331 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 48,972 shares of company stock valued at $12,295,205 in the last 90 days. Insiders own 0.16% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Constructive post-earnings outlook: JNJ’s latest results exceeded analyst expectations for both earnings and revenue, while full-year 2026 EPS guidance remains centered around $11.60-$11.75. Analysts are watching for continued estimate increases and earnings momentum to support the stock’s advance. Why Is Johnson & Johnson Up Since Its Last Earnings Report?
• Positive Sentiment: Pharmaceutical recovery and defensive appeal: JNJ is among the large-cap pharmaceutical companies investors are watching as the industry recovery gains traction. Its diversified healthcare business and relatively low-beta profile may also attract investors seeking defensive exposure amid market uncertainty. Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
• Positive Sentiment: Dividend record reinforces income appeal: JNJ raised its dividend 3.1% to $5.36 per share annually, extending its streak of consecutive increases to 64 years. The increase supports the company’s reputation as a long-term income and stability investment. Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years
• Neutral Sentiment: Talc settlement remains a key overhang: Analysis of JNJ’s proposed $5.5 billion talc settlement views it as a potential step toward reducing litigation uncertainty, but the long-term financial and legal impact remains subject to scrutiny. Johnson & Johnson’s $5.5B Talc Settlement
• Neutral Sentiment: Portfolio adjustments: JNJ sold its remaining rights and interests in botaretigene sparoparvovec to MeiraGTx for $25 million. The transaction may streamline the portfolio, but its financial contribution is unlikely to materially affect near-term results. MeiraGTx Reports Second Quarter 2026 Results
• Negative Sentiment: Robotics competition is increasing: Intuitive Surgical cited growing competitive pressure from JNJ and Chinese robotic-surgery platforms. While this reflects JNJ’s ambitions in surgical robotics, it also signals that gaining market share could require substantial investment and execution. Intuitive Surgical Beats on Q2 Results

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $260.44 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $627.63 billion, a price-to-earnings ratio of 30.18, a P/E/G ratio of 2.48 and a beta of 0.24. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $274.90. The firm’s 50-day simple moving average is $251.92 and its two-hundred day simple moving average is $241.20.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 62.11%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on JNJ. Bank of America raised their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday, July 6th. Citigroup raised their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Finally, Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $268.22.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.